National Institutes for Quantum and Radiological Science and Technology

Kyoto University

National Institute of Radiological Sciences

Yokohama City University

Makoto Higuchi

Tetsuya Suhara

Meiei Cho

Masahiro Maruyama

Hitoshi Shimada

Haruhisa Inoue

Hiroki Takeuchi

Ryosuke Takahashi

Bin Ji

Tomoyuki Miyazaki

Takuya Takahashi

The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof:

Compounds for imaging tau proteins that accumulate in the brain

The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein:  represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.

Compounds for imaging tau proteins that accumulate in brain

The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: 

The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. (In the formula, each of A and Z independently represents CO, SO or SO; each of X and Y independently represents S or O; each of R-Rindependently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a halogen group; each Rindependently represents an alkyl group, an alkenyl group, an alkynyl group or a halogen group; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.

Compound that specifically binds to AMPA receptor

This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phospholylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.

Vaccine for treatment of tautopathy

This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.

Growing community of inventors

Chiba, Japan

Makoto Higuchi